Lazard Asset Management LLC Bei Gene, Ltd. Transaction History

Lazard Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $762,528 - $1.23 Million	-3,055 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$292.75 - $367.01 $894,351 - $1.12 Million	3,055 New	3,055 $1.05 Million
Q1 2021 May 14, 2021	SELL	$260.64 - $382.12 $179,580 - $263,280	-689 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $130,345 - $197,357	689 New	689 $197,000
Q1 2018 May 14, 2018	SELL	$97.41 - $177.22 $153,907 - $280,007	-1,580 Closed	0 $0
Q4 2017 Aug 28, 2019	BUY	$79.6 - $114.73 $46,168 - $66,543	580 Added 58.0%	1,580 $154,000
Q4 2017 Feb 13, 2018	BUY	$79.6 - $114.73 $79,600 - $114,730	1,000	1,000 $97,000

254

42.4M

135K

111K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.